Latest Commercialisation News

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Patagonia Lithium Limited reports a maiden mineral resource estimate of 717,000 tonnes of lithium metal equivalent and advances exploration in Argentina and Brazil, while navigating critical funding negotiations to support its 2025 growth plans.

Mad Paws Holdings Limited reported a milestone positive cash EBITDA of $0.3 million in Q2 FY25, driven by strong marketplace growth and operational efficiencies. The company is amplifying its market presence with a $5.25 million brand campaign in partnership with Seven West Media.

Top End Energy has taken a major step by acquiring the Kansas Natural Hydrogen Project and advancing its exploration footprint in Australia's Beetaloo Sub-Basin, positioning itself at the forefront of natural hydrogen and unconventional gas development.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

Blue Star Helium has secured strategic helium and oil and gas assets in Colorado, partnered with Helium One to fund drilling, and raised A$3 million, positioning itself for production growth in 2025.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Altech Batteries Limited has made significant strides in funding and technology for its CERENERGY® battery project, including a $4 million capital raise and a breakthrough 55% increase in lithium-ion battery anode energy density.